mozobil Report issue

Small molecule Experimental First in Class
AACT ChEMBL Drug Central PubChem

Active Ingredient History

NOW
  • Now
Plerixafor is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients into the bloodstream. The stem cells are then extracted from the blood and transplanted back to the patient. The drug was developed by AnorMED, which was subsequently bought by Genzyme.   Wikipedia

Chemistry

  • SMILES: C(N1CCCNCCNCCCNCC1)c2ccc(CN3CCCNCCNCCCNCC3)cc2
  • InChIKey: YIQPUIGJQJDJOS-UHFFFAOYSA-N
  • Mol. Mass: 502.8
  • ALogP: 0.42
  • ChEMBL Molecule:
    plerixafor  
More Chemistry

Pharmacology

  • Mechanisms of Action: Missing data
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

gz316455 | mozobil

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Lymphoma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasm Metastasis (Phase 1)

Osteosarcoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue